Full access to Entrepreneur for $5
Subscribe

Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System

Thermo Fisher's (TMO) Nano-Capillary and Micro-Flow LC Systems will benefit principal investigators, laboratories and proteomics researchers in academ...

By
This story originally appeared on Zacks

Thermo Fisher Scientific Inc. TMO recently announced the introduction of the new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns, which help users overcome limitations of the existing low-flow LC instruments.  The system is intended for high sensitivity LC-mass spectrometry (LC-MS) applications, technical capabilities and easy integration with Thermo Scientific PepMap Neo Columns and Thermo Scientific mass-spectrometry portfolio.

- Zacks

The recent development will enhance Thermo Fisher’s high performance chromatography solutions.

More on the News

The new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns provide application flexibility and robust analytical performance at flow rates from 1 nL/min -100 µL/min. This can go up to 1500 bar. Novice and expert LC-MS users will enjoy high productivity, minimized method overhead time, and long-term operation essential for 24/7 large sample cohort analysis.

The all-in-one nano- capillary- and micro-flow liquid chromatography (LC) system will benefit principal investigators, laboratories, and proteomics researchers in academia, biopharma and contract research organizations.

Zacks Investment ResearchImage Source: Zacks Investment Research

The new system provides seamless integration with the comprehensive portfolio of Thermo Scientific mass spectrometers and will enhance quantitation through high-injection volume linearity, precision and accuracy.

Significance of the Launch

Per Thermo Fisher’s management, the Vanquish Neo UHPLC System and PepMap Neo Columns will enable long-term operation with maximum performance levels without compromise.

The Vanquish Neo UHPLC System will change the conventional way of performing proteomics studies by offering the long-term robustness and flow-range versatility required for deep and quick LC-MS profiling of thousands of proteomes together with PepMap Columns and high-resolution accurate mass (HRAM) systems.

Industry Prospects

Per a report by MARKETANDMARKETS, the global chromatography instruments market is expected to rise from $8.6 billion in 2020 to $11.0 billion by 2025, at a CAGR of 5.1%. Growing investments in the pharmaceutical R&D and rising food safety concerns worldwide are the factors driving the market.

Recent Developments

In September 2021, Thermo Fisher announced that lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from the Thermo Scientific TSQ Plus triple quadrupole mass spectrometer (MS) portfolio, which increases workflow throughput through superior data acquisition and polarity switching speeds.

In the same month, Thermo Fisher and AstraZeneca AZN collaborated under a multiyear global agreement to co-develop next-generation sequencing based companion diagnostics (CDx). Through the agreement, the companies aim to grow AstraZeneca’s portfolio of targeted therapies.

Price Performance

Shares of the company have gained 36.4% in a year’s time compared with the industry’s rise of 19.5%.

Zacks Rank and Key Picks

Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).

A couple of better-ranked stocks from the broader medical space are Envista Holdings Corporation NVST and BellRing Brands, Inc. BRBR, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.

Envista Holdings has an estimated long-term earnings growth rate of 27%.

BellRing Brands has an estimated long-term earnings growth rate of 29%.



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

AstraZeneca PLC (AZN): Free Stock Analysis Report

 

Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

 

Envista Holdings Corporation (NVST): Free Stock Analysis Report

 

BellRing Brands, Inc. (BRBR): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research